Development of a Stable Cell Line, Overexpressing Human T-cell Immunoglobulin Mucin 1

Authors

  • Hossein khanahmad Department of Genetic and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran **- co-corresponding author
  • Ilnaz Rahimmanesh Department of Genetic and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Jafar Majidi Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
  • Mazdak Ganjalikhani-hakemi *Cellular and Molecular Immunology Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran * corresponding author
  • Mina Ebrahimi Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran Students’ Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
  • Shirin Kohpayeh Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Tohid Kazemi Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
  • Vida Homayouni Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract:

Background: Recent researches have demonstrated that human T-cell immunoglobulin mucin 1 (TIM-1) glycoprotein plays important roles in regulation of autoimmune and allergic diseases, as well as in tumor immunity and response to viral infections. Therefore,targeting TIM-1 could be a potential therapeutic approach against such diseases. Objectives: In this study, we aimed to express TIM-1 protein on Human Embryonic kidney (HEK) 293T cell line in order to have an available source of the TIM-1 antigen. Materials and Methods: The cDNA was synthesized after RNA extraction from peripheral blood mononuclear cells (PBMC) and TIM-1 cDNA was amplified by PCR with specific primers. The PCR product was cloned in pcDNA™3.1/Hygro (+) and transformed in Escherichia coli TOP 10 F’. After cloning, authenticity of DNA sequence was checked and expressed in HEK 293T cells. Finally, expression of TIM-1 was analyzed by flow cytometry and real-time PCR. Results: The result of DNA sequencing demonstrated correctness of TIM-1 DNA sequence. The flow cytometry results indicated that TIM-1 was expressed in about 90% of transfected HEK 293T cells. The real-time PCR analysis showed TIM-1 mRNA expression increased 195-fold in transfected cells compared with un-transfected cells. Conclusions: Findings of present study demonstrated the successful cloning and expression of TIM-1 on HEK 293T cells. These cells could be used as an immunogenic source for production of specific monoclonal antibodies, nanobodies and aptamers against human TIM-1.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

development of a stable cell line, overexpressing human t-cell immunoglobulin mucin 1

background: recent researches have demonstrated that human t-cell immunoglobulin mucin 1 (tim-1) glycoprotein plays important roles in regulation of autoimmune and allergic diseases, as well as in tumor immunity and response to viral infections. therefore,targeting tim-1 could be a potential therapeutic approach against such diseases.objectives: in this study, we aimed to express tim-1 protein ...

full text

Stimulation of Camel Polyclonal Antibody against Human T cell Immunoglobulin and Mucin 3

Background: T cell Immunoglobulin, Mucin (TIM)-3, is a type I transmembrane glycoprotein belonging to TIM family. This receptor expresses on T helper type 1 (Th1) cells that binds to galectin-9 (Gal9); inducing an inhibitory signal. As a result, apoptosis of Th1 cells occurs and cytotoxicity of CD8 T cells becomes evident in vitro. Therefore, this immunomodulatory molecule may ...

full text

Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)

Objective(s): As T-cell immunoglobulin and mucin domain 3 (TIM-3) is an immune regulatory molecule; its blocking or stimulating could alter the pattern of immune response towards a desired condition. Based on the unique features of nanobodies, we aimed to construct an anti-TIM-3 nanobody as an appropriate tool for manipulating immune responses for future therapeutic purposes. Materials and Meth...

full text

T Cell Immunoglobulin Mucin Domain (TIM)-3 Promoter Activity in a Human Mast Cell Line

T cell immunoglobulin mucin domain (TIM)-3 is an immunomodulatory molecule and upregulated in T cells by several cytokines. TIM-3 also influences mast cell function but its transcriptional regulation in mast cells has not been clarified. Therefore, we examined the transcript level and the promoter activity of TIM-3 in mast cells. The TIM-3 transcript level was assessed by real-time RT-PCR and p...

full text

Generation of CHO Stable Cell Line Overexpressing HER2: an In Vitro Model for Breast Cancer

Background: Breast cancer is the most common female malignancy and the leading cause of cancer mortality in women worldwide. The human epidermal growth factor receptor2 (HER2) is a transmembrane tyrosine kinase receptor that is usually overexpressed in human breast cancers. Stable cell lines heterogeneously overexpressing HER2 are highly required as in vitro models for breast cancer research. T...

full text

preparation and characterization of a novel nanobody against t-cell immunoglobulin and mucin-3 (tim-3)

objective(s): as t-cell immunoglobulin and mucin domain 3 (tim-3) is an immune regulatory molecule; its blocking or stimulating could alter the pattern of immune response towards a desired condition. based on the unique features of nanobodies, we aimed to construct an anti-tim-3 nanobody as an appropriate tool for manipulating immune responses for future therapeutic purposes. materials and meth...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 13  issue 4

pages  25- 31

publication date 2015-12-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023